• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Indevus Names Steven M. Lyons, PhD, Senior Vice President of Program Management

Posted on: Wednesday, 26 October 2005, 09:01 CDT

Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced that it has named Steven M. Lyons, PhD, MBA to the newly created position of senior vice president, program management. Dr. Lyons has more than 20 years experience in program management, marketing, business development and business analysis in the pharmaceutical industry. In his position, Dr. Lyons will be responsible for implementing a multi-disciplinary program management system at Indevus to increase the speed and efficiency of the Company's product development activities.

"We are very pleased to have Steve joining the management team at Indevus," said Glenn L. Cooper, M.D., president, chairman and chief executive officer of Indevus. "Program management is an effective tool for facilitating pharmaceutical product development. Steve's proven accomplishments in the area of program management will assist the Company tremendously as we continue to move our focused urology, gynecology and men's health strategy forward. Given the number of products we have in our pipeline including NEBIDO(R) for male hypogonadism, PRO 2000 for HIV and STD prevention, IP 751 for interstitial cystitis and SANCTURA XR(TM), Steve's leadership will be instrumental in the successful coordination of various product development activities and project teams."

Prior to joining Indevus, Dr. Lyons held a number of management positions at various biotechnology and pharmaceutical companies. Most recently, Dr. Lyons held the position of program executive at Vertex Pharmaceuticals, Inc. where he was responsible for leadership of cross-functional program teams with oversight responsibility for preclinical development, clinical trial design, manufacturing, regulatory strategy, management of project budgets and strategic partnering. From 1995 to 1998, Dr. Lyons held positions in business development and strategic marketing with Novartis Pharmaceuticals. From 1990 to 1995 Dr. Lyons was with Sandoz Pharmaceuticals Corporation, which merged with Ciba-Geigy in 1996 to form Novartis, with responsibilities in pre-launch marketing planning, portfolio management, multisource marketing, and oncology business development. Prior to joining Sandoz Pharmaceuticals, Dr. Lyons was with Biogen, Inc. from 1985 to 1990.

About Indevus

Indevus Pharmaceuticals is a biopharmaceutical company engaged in the acquisition, development and commercialization of products targeting certain medical specialty areas, including urology and gynecology. The Company currently markets SANCTURA(R) for overactive bladder and has multiple compounds in clinical development, including SANCTURA XR(TM), the once-daily formulation of SANCTURA, NEBIDO(R) for the treatment of male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually transmitted pathogens, IP 751 for interstitial cystitis, pagoclone for stuttering, and aminocandin for systemic fungal infections.

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA(TM) and SANCTURA XR(TM); the early stage of products under development; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA and SANCTURA XR; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR; dependence on third parties for manufacturing and marketing; competition; need for additional funds and corporate partners, including for the development of our products; failure to acquire and develop additional product candidates; history of operating losses and expectation of future losses; product liability and insurance uncertainties; risks relating to the Redux-related litigation; limited patent and proprietary rights; dependence on market exclusivity; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; and other risks.

Source: Business Wire

More News in this Category